Oxidative and antioxidative status after anthracycline-based chemotherapy in breast cancer patients

被引:1
|
作者
Alacacioglu, A. [1 ]
Kebapcilar, L. [2 ]
Pamuk, B. Onder [2 ]
Sop, G. [2 ]
Kucukiravul, C. [2 ]
Bozkaya, G. [3 ]
Yuksel, A. [2 ]
Alacacioglu, I. [4 ]
Sari, I. [2 ]
机构
[1] Bozyaka Res & Training Hosp, Dept Med Oncol, TR-35360 Izmir, Turkey
[2] Bozyaka Res & Training Hosp, Dept Internal Med, TR-35360 Izmir, Turkey
[3] Bozyaka Res & Training Hosp, Dept Biochem, TR-35360 Izmir, Turkey
[4] Ataturk Training & Res Hosp, Dept Hematol, Izmir, Turkey
来源
JOURNAL OF BUON | 2013年 / 18卷 / 03期
关键词
anthracycline; breast cancer; SOD; TBARS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The present study was undertaken to evaluate the effects of adjuvant anthracycline-based chemotherapy on thiobarbituric acid reactive substances (TBARS) and superoxide dismutase (SOD) levels in patients with breast cancer who had undergone surgery. Methods: Body mass index (BMI), serum lipids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), serum TBARS and SOD values were assessed in 30 patients with stage III breast cancer receiving adjuvant anthracydine-based chemotherapy. Results: Anthracycline-based chemotherapy had no effect on BMI, blood pressure and lipid profile. A significant elevation was noted in TBARS (5.5 +/- 0.6 vs 5.9 +/- 0.9}anon; p=0.038) and a significant reduction to baseline values in SOD levels (226.5 +/- 61.0 vs 203.1 +/- 48.3 U/mL; p=0.037) in patients following 6 cycles of adjuvant chemotherapy. Conclusion: The TBARS levels increased, whereas the SOD levels descreased after anthracycline-based chemotherapy. We suggest that oxidative stress is not always detrimental, as it can be beneficial in cancer treatment.
引用
收藏
页码:614 / 618
页数:5
相关论文
共 50 条
  • [41] Risk of cardiotoxicity induced by adjuvant anthracycline-based chemotherapy and radiotherapy in young and old Asian women with breast cancer
    Lee, Chih-Hsin
    Zhang, Jun-Fu
    Yuan, Kevin Sheng-Po
    Wu, Alexander T. H.
    Wu, Szu-Yuan
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (07) : 629 - 639
  • [42] Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer
    Teraoka, Saeko
    Sato, Eiichi
    Narui, Kazutaka
    Yamada, Akimitsu
    Fujita, Tomoyuki
    Yamada, Kimito
    Oba, Mari
    Ishikawa, Takashi
    JOURNAL OF SURGICAL RESEARCH, 2020, 250 : 143 - 147
  • [43] Subclinical myocardial damage after anthracycline chemotherapy in Japanese patients with breast cancer
    Nakatsuma, Kenji
    Ozasa, Neiko
    Ohno, Mikiko
    Ishiguro, Hiroshi
    Minami, Manabu
    Nishi, Eiichiro
    Toi, Masakazu
    Ono, Koh
    Kimura, Takeshi
    JOURNAL OF CARDIOLOGY, 2024, 84 (04) : 260 - 265
  • [44] Effects of the Chinese herbal medicine Hong Huang decoction, on myocardial injury in breast cancer patients who underwent anthracycline-based chemotherapy
    Cao, Sihan
    Xue, Jingxian
    Chen, Lu
    Hao, Yun
    Lu, Meijuan
    Feng, Ming
    Wang, Huanhuan
    Zhou, Jun
    Yao, Chang
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [45] The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer
    Mills, PJ
    Parker, B
    Dimsdale, JE
    Sadler, GR
    Ancoli-Israel, S
    BIOLOGICAL PSYCHOLOGY, 2005, 69 (01) : 85 - 96
  • [46] The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer
    Woolston, Caroline M.
    Zhang, Lei
    Storr, Sarah J.
    Al-Attar, Ahmad
    Shehata, Mohamed
    Ellis, Ian O.
    Chan, Stephen Y.
    Martin, Stewart G.
    MODERN PATHOLOGY, 2012, 25 (08) : 1106 - 1116
  • [47] Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer
    Ishitobi, Makoto
    Komoike, Yoshifumi
    Motomura, Kazuyoshi
    Koyama, Hiroki
    Inaji, Hideo
    ONCOLOGY, 2010, 78 (3-4) : 213 - 219
  • [48] Effect of primary anthracycline-based chemotherapy on disseminated tumor cells in locally advanced breast cancer
    Jäger, C
    Kafka, A
    Bossert, S
    Grundmann, R
    Windisch, J
    Kreienberg, R
    Heilmann, V
    ANTICANCER RESEARCH, 2004, 24 (5B) : 3209 - 3214
  • [49] Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy
    Martin-Richard, M
    Muñoz, M
    Albanell, J
    Colomo, L
    Bellet, M
    Rey, MJ
    Tabernero, J
    Alonso, C
    Cardesa, A
    Gascon, P
    Fernandez, PL
    ONCOLOGY, 2004, 66 (05) : 388 - 394
  • [50] Cardiac Tolerability of Concurrent Administration of Trastuzumab and Anthracycline-Based Regimen as Adjuvant Chemotherapy for Breast Cancer
    Watanabe, Naoki
    Otsuka, Shoko
    Sasaki, Yoko
    Shimojima, Reiko
    Wani, Yoji
    Uchino, Kaori
    BREAST CARE, 2014, 9 (01) : 46 - 51